Most common adverse reactions:
- Nausea: 37.9% (11) with AZD4635, 53.3% (16) with durvalumab oleclumab
- Feeling tired: 20.7% (6) with AZD4635, 30.0% (9) with durvalumab oleclumab
- Decreased appetite: 17.2% (5) with AZD4635, 16.7% (5) with durvalumab oleclumab
- Vomiting: 10.3% (3) with AZD4635, 23.3% (7) with durvalumab oleclumab
- Diarrhea: 13.8% (4) with AZD4635, 10.0% (3) with durvalumab oleclumab
- Feeling dizzy: 13.8% (4) with AZD4635, 6.7% (2) with durvalumab oleclumab
- Constipation: 10.3% (3) with AZD4635, 3.3% (1) with durvalumab oleclumab
- Low amount of a type of blood cell called platelets (which help blood to clot): 0.0% (0) with AZD4635, 6.7% (2) with durvalumab oleclumab
- Difficulty sleeping: 6.9% (2) with AZD4635, 0.0% (0) with durvalumab oleclumab
- High blood pressure: 0.0% (0) with AZD4635, 6.7% (2) with durvalumab oleclumab
- Pain in the stomach: 6.9% (2) with AZD4635, 0.0% (0) with durvalumab oleclumab
- Disease where stomach acid often goes upwards into the tube connecting the mouth and stomach: 3.4% (1) with AZD4635, 3.3% (1) with durvalumab oleclumab
- Itching: 3.4% (1) with AZD4635, 3.3% (1) with durvalumab oleclumab
- Rash: 3.4% (1) with AZD4635, 3.3% (1) with durvalumab oleclumab
- Swelling of lower legs or hands: 6.9% (2) with AZD4635, 0.0% (0) with durvalumab oleclumab
- Increased amounts in the blood of a type of protein called amylase that helps digest food: 3.4% (1) with AZD4635, 3.3% (1) with durvalumab oleclumab

How has this study helped patients and researchers?
This study helped researchers learn more about how AZD4635 with durvalumab or with oleclumab worked in participants with prostate cancer. Researchers look at the results of many studies to decide which treatments work best and are safest. This summary shows only the main results from this one study. Other studies may provide new information or different results. Further clinical studies with AZD4635 with durvalumab and with oleclumab are not planned by the sponsor at this time.